Andere talen Alzamend Neuro, Inc.

Aandelen

ALZN

US02262M4078

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,711 ^USD	+0,14%		-2,01%	-20,11%

25/03	Alzamend Neuro, Inc. rapporteert de winstresultaten voor het derde kwartaal en de negen maanden eindigend op 31 januari 2024	CI
05/01	Alzamend Neuro, Inc. Benoemt Milton C. Ault, III tot Bestuurder en Vice-Voorzitter	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	25/03
Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC	31/01
Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman	05/01
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	15/12
Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	12/12
Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	11/12
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	11/12
Alzamend Neuro Receives FDA Approval to Proceed With Phase 2A Study of AL001 Depression Treatment Candidate	20/11
Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment	20/11
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	20/11
Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	20/11
Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement	17/11
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement	16/11
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001	13/11
Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001	13/11
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	30-10-23
Alzamend Neuro Announces Reverse Stock Split	30-10-23
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next-Generation Lithium Therapeutic Drug Candidate AL001	24-10-23
Alzamend Neuro Seeks FDA Nod to Start Trial in Major Depressive Disorder	23-10-23
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001	23-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Alzamend Neuro, Inc.

Aandelen

ALZN

US02262M4078

Andere talen

Filters